Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,671 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
Hasegawa Y, Kawaguchi T, Kubo A, Ando M, Shiraishi J, Isa S, Tsuji T, Tsujino K, Ou SH, Nakagawa K, Takada M. Hasegawa Y, et al. Among authors: kawaguchi t. J Thorac Oncol. 2011 Nov;6(11):1881-8. doi: 10.1097/JTO.0b013e31822722b6. J Thorac Oncol. 2011. PMID: 21841503 Free article.
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group. Shukuya T, et al. Among authors: kawaguchi t. Lancet Oncol. 2015 Dec;16(16):1630-8. doi: 10.1016/S1470-2045(15)00305-8. Epub 2015 Oct 28. Lancet Oncol. 2015. PMID: 26522337 Clinical Trial.
Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-small Cell Lung Cancer: The Final Report.
Yoshimura N, Tada T, Matsumoto Y, Sawa K, Yoshimoto N, Suzumura T, Tanaka H, Mitsuoka S, Kimura T, Tamiya T, Hirashima T, Kawaguchi T, Kudoh S, Hosono M, Hirata K. Yoshimura N, et al. Among authors: kawaguchi t. Am J Clin Oncol. 2018 Oct;41(10):967-971. doi: 10.1097/COC.0000000000000412. Am J Clin Oncol. 2018. PMID: 29045265 Clinical Trial.
Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L).
Kimura T, Kawaguchi T, Chiba Y, Yoshioka H, Watanabe K, Kijima T, Kogure Y, Oguri T, Yoshimura N, Niwa T, Kasai T, Hayashi H, Ono A, Asai K, Tanaka H, Yano S, Yamamoto N, Nakanishi Y, Nakagawa K. Kimura T, et al. Among authors: kawaguchi t. Jpn J Clin Oncol. 2019 Oct 1;49(10):947-955. doi: 10.1093/jjco/hyz088. Jpn J Clin Oncol. 2019. PMID: 31242302 Clinical Trial.
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Matsumoto Y, Sawa K, Fukui M, Oyanagi J, Izumi M, Ogawa K, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Kimura T, Yamamoto N, Koh Y, Kawaguchi T. Matsumoto Y, et al. Among authors: kawaguchi t. Cancer Sci. 2019 Oct;110(10):3244-3254. doi: 10.1111/cas.14156. Epub 2019 Aug 30. Cancer Sci. 2019. PMID: 31368625 Free PMC article.
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Matsumoto Y, Sawa K, Fukui M, Oyanagi J, Yoshimoto N, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Kimura T, Yamamoto N, Hirata K, Koh Y, Kawaguchi T. Matsumoto Y, et al. Among authors: kawaguchi t. Lung Cancer. 2020 Jan;139:80-88. doi: 10.1016/j.lungcan.2019.10.029. Epub 2019 Nov 2. Lung Cancer. 2020. PMID: 31751804
2,671 results